Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of eye allergies within the past 24 months~* Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period~Exclusion Criteria:~* Current eye infection~* Eye surgery within 3 months or vision correction surgery within 6 months~* Any planned surgery during the study or 30 days after the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LASTACAFT® (alcaftadine 0.25%) (Type: ACTIVE_COMPARATOR): One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
- Pataday™ (olopatadine 0.2%) (Type: ACTIVE_COMPARATOR): One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
- Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) (Type: PLACEBO_COMPARATOR): One drop of placebo instilled in each eye at Day 0 and Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).